← All trials
NCT01978730
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2011
- Primary completion
- Jul 1, 2014
- Completion date
- Jul 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 372
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Shineway Pharmaceutical Co.,LtdLead sponsor
- Capital Medical UniversityOverall official - principal investigator
- Shanghai University of Traditional Chinese MedicineStudy chair
- Southern Medical UniversityStudy chair
- Tianjin UniversityStudy chair
- Zhejiang UniversityStudy chair
- Hospital of Traditional Chinese and Western Medicine of Jilin ProvinceStudy chair
- Southeast UniversityStudy chair
- Nanjing Medical UniversityStudy chair
- Guangzhou UniversityStudy chair
- First People's Hospital of ChenzhouStudy chair
- Peking UniversityStudy chair
- Baotou Medical UniversityStudy chair
- Capital Medical UniversityStudy chair
- Chengdu University of Traditional Chinese MedicinesStudy chair
- Hunan University of Traditional Chinese MedicineStudy chair
- Jilin UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.